Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploratory Study on the Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable Hepatocellular Carcinoma

NCT06904014 is registered in ClinicalTrials.gov with Lei ZHAO as lead sponsor.

NCT NCT06904014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06904014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploratory Study on the Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable Hepatocellular Carcinoma
Lead sponsor
Lei ZHAO
Phase
Phase 2
Overall status
Recruiting
Start date
October 25, 2023
Completion date
June 30, 2029
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hcc